FDA Determines Regulatory Review Period for Edwards Pericardial Aortic Bioprosthesis

Summary

The US Food and Drug Administration has officially set a review period for patent extension applications for Edwards' pericardial aortic bioprosthesis, a medical device, following a submission to the US Patent and Trademark Office.